NIST announces the first four quantum-resistant cryptographic algorithms

The first four algorithms NIST has announced for post-quantum cryptography are based on structured lattices and hash functions, two families of mathematical problems that could resist attack by a quantum computer. Recognition: N. Hanacek/NIST GAITHERSBURG, Md. – The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) has selected the first group of … Read more

The Justice Department announces an enforcement action that will indict six people for cryptocurrency fraud offenses in cases involving intended losses in excess of $100 million

The Department of Justice, along with federal law enforcement partners, today announced criminal charges against six defendants in four separate counts for their alleged involvement in cryptocurrency-related fraud, including the largest known Non-Fungible Token (NFT) scheme to date, which has been charged with being a fraudulent Mutual fund allegedly traded on cryptocurrency exchanges, a global … Read more

Kezar Life Sciences announces positive top-line results from the Phase 2 MISSION study evaluating zetomipzomib for the treatment of patients with lupus nephritis

11 of 17 patients (64.7%) achieves a general renal response 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months Six of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less, at 6 months Zetomipzomib continues to show a favorable safety and tolerability profile when … Read more

Dell Announces All-New, Redesigned XPS 13 and XPS 13 2-in-1 Premium Laptops and Folio PCs for 2022

Dell has announced the all-new XPS 13 (9315) and XPS 13 2-in-1 (9315) premium laptop and folio PC. The new XPS 13 has a motherboard that is 1.8x smaller than last year’s model, making it the most compact XPS 13 yet. Both laptops feature Intel 12th generation U-series processors, and the 2-in-1 offers optional 5G … Read more

Cogent Biosciences announces positive initial clinical data from the ongoing Phase 2 APEX study evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Cogent Biosciences, Inc. All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89% regardless of prior treatment with the KIT-D816V inhibitor All patients who underwent bone marrow biopsy scored ≥50% reduction in bone marrow mast cells and reduction in allelic fraction of variant KIT D816V in blood (VAF) … Read more